| abstract |
Benzimidazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection, where W, X, Y and Z can be independently C-R2, C-R3, C-R4, C-R5 or N; A is a 5 or 6 member heterocyclic ring containing at least one of N, O or S. |